First-in-class synthetic lysin

Medical need:

Bacterial vaginosis

High efficacy,

high precision


Gardnerella spp.

Patient population:

1 in 4 women (aged 15-49) p.a. globally


60% within 6 months

Current standard-of-care:

Broad-spectrum antibiotics (acute) and long-term suppressive antibiotics (chronic)

Cleaving domain

PM-477 has a cleaving domain. After it binds to the cell wall, it lyses it. The cell bursts and the bacteria die.

Binding domain

PM-477 has a Gardnerella specific binding domain. It only binds to the cell wall of Gardnerella bacteria. It is specific.


Target pathogen: Gardnerella spp.

Indication: recurrent bacterial vaginosis


Lead optimization


Phase I

Phase II

pm-477 thumbnail

Read our Publication in Pathogens

The first publication detailing PM-477 is now available.  

Scientific Advisory Board

Prof. Dr. med. Werner Mendling

Prof. Dr. Christina Muzny

Dr. Gregory Resch

Prof. Dr. Jane Schwebke

Prof. Dr. Jack Sobel

PD Dr. Alexander Swidsinski

Prof. Dr. Mario Vaneechoutte

PhagoMed Biopharma GmbH

Leberstraße 20

1110 Vienna


Imprint & Privacy Policy